Jin Lei
14 Papers
2 Citations
Jin Lei is an academic researcher. The author has contributed to research in topics: Medicine & Hepatocellular carcinoma. The author has an hindex of 2, co-authored 12 publications.
Chat about Author
Papers
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients
Xu Yang,Bowen Chen,Yanyu Wang,Yunchao Wang,Junyu Long,Na Zhang,Jing Xue,Ziyu Xun,Lin-Zhi Zhang,Jiamin Cheng,Jin Lei,Huishan Sun,Yiran Li,Jianzhen Lin,Fucun Xie,Dongxu Wang,Jie Pan,Ke-Xing Hu,M. Guan,Li Huo,Jie Shi,Ling-xiang Yu,Lin Zhou,Jin-Rhong Zhou,Zhenhui Lu,Xiaobo Yang,Yilei Mao,Xinting Sang,Yinying Lu,Haitao Zhao +29 more
TL;DR: Wang et al. as mentioned in this paper investigated the real-world efficacy of and prognostic factors for survival associated with lenvatinib plus PD-1 inhibitor treatment in a large cohort of Asian uHCC patients even the global LEAP-002 study failed to achieve the primary endpoints.
TM4SF1 upregulates MYH9 to activate the NOTCH pathway to promote cancer stemness and lenvatinib resistance in HCC
TL;DR: In this paper , the effect of transmembrane 4 superfamily on cancer stemness in hepatocellular carcinoma (HCC) and its molecular basis are yet to be reported.
TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure
TL;DR: In this article , the combination of TKI and PD-1 inhibitors was evaluated in patients with hepatocellular carcinoma (uHCC) after sorafenib failure.
Efficacy and Safety of TKI Plus PD-1 Inhibitors in Elderly uHCC Patients: A Retrospective Study
Bowen Chen,Jin Lei,Haitao Zhao,Jinghui Dong,Zhen Zeng,Yinying Lu,Ling-xiang Yu,Lin Zhou,Aiying Jia,Jiamin Cheng +9 more
TL;DR: In this article , the efficacy and safety of sorafenib- or lenvatinib-based combination therapy with PD-1 inhibitors in elderly patients aged ≥75 years with unresectable hepatocellular carcinoma (uHCC) were continually reviewed.
3
Lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma: A large real-world study from two centers.
Xu Yang,Bowen Chen,Yanyu Wang,Yunchao Wang,Junyu Long,Ning Zhang,Jinnan Xue,Ziyu Xun,Lin-Zhi Zhang,Jiamin Cheng,Jin Lei,Jie Pan,Ke-Xing Hu,Mei Guan,Li Huo,Yilei Mao,Xinting Sang,Yinying Lu,Haitao Zhao +18 more
TL;DR: This real-world study of lenvatinib plus PD-1 inhibitors achieved long survival and considerable ORR for uHCC patients in China and the tolerability of combination therapy was acceptable but should be still monitored closely.
2